Patient Support Hotline

Call (844) 244-1309

ZERO360 is a free, comprehensive patient support service to help patients and their families navigate insurance and financial obstacles to cover treatment and other critical needs associated with cancer.


Subscribe to our E-Newsletter

Stay up-to-date on the latest news about prostate cancer. Join our distribution list to receive periodic email updates and our monthly e-newsletter.

  • Patient Support (844) 244-1309
  • Search
  • e-News Signup Enews Signup
  • Run/Walk
  • Donate

- test

Investigating CD133 as a Biomarker of Prostate Cancer Disparity in African American Men

Both prostate cancer incidence and prostate cancer-specific mortality are higher in African American men compared with Caucasian men. In this... Read More

SBRT Appears Effective for Oligometastatic Prostate Cancer

Stereotactic body radiation therapy (SBRT) appears to be an effective treatment for oligometastatic disease in patients with recurrent prostate cancer, a... Read More

Gene Variant May Affect Response to Abiraterone in Certain Men with Prostate Cancer

A new study has shown that a genetic anomaly found in certain men with prostate cancer — a variant in HSD3B1 —... Read More

Partial Brachytherapy May Lead to Poor Outcomes in Intermediate-Risk Prostate Cancer

Partial prostate treatment with MRI-guided brachytherapy may lead to poor outcomes long-term among patients with intermediate-risk prostate cancer, according to a... Read More

New Therapeutic Directions in the Management of Prostate Cancer

Efforts to unravel prostate cancer’s genetic fingerprints lag behind other cancers, notably breast cancer, experts agree. But, mutations seen in the... Read More

Enzalutamide for Advanced Prostate Cancer Does Not Worsen HRQoL

Enzalutamide delays metastasis in men with non-metastatic castration̶resistant prostate cancer (CRPC) without worsening health-related quality of life (HRQoL) and significantly decreases the... Read More

Active Surveillance May Be Safe for Selected Men With Gleason 3+4 Prostate Cancer

New findings support the safety of including selected men with Gleason 3+4 prostate cancer in active surveillance (AS) programs, Australian researchers reported... Read More

Diet and Dosage: How Much Could Patients Save?

The authors of a recent prostate cancer study claim that a drug manufacturer and the US Food and Drug Administration... Read More

Preventive Benefit of Finasteride for Prostate Cancer Maintained for 16 Years

The Prostate Cancer Prevention Trial (PCPT) showed that the use of finasteride, a 5-alpha-reductase inhibitor, for 7 years reduced the... Read More

Adding Mitoxantrone to Adjuvant ADT Not Recommended for High-Risk Prostate Cancer

Adding mitoxantrone and prednisone (MP) to adjuvant androgen-deprivation therapy (ADT) does not improve overall survival (OS) or disease-free survival (DFS)... Read More

1 2 3 5